International Journal of Cancer Management

Published by: Kowsar

Prevalence of the Vascular Endothelial Growth Factor Receptor (VEGER) in Transitional Cell Carcinoma (TCC) of Bladder and its Relationship with Other Prognostic Factors

Hamidreza Mirzaei 1 , Parisa Sabetrasekh 1 , Parto Sabetrasekh 1 , Mahmoud Parvin 2 , Peyman Torbati 2 and Parastoo Hajian 3 , *
Authors Information
1 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Radiation Oncology, Shohadaye Tajrish Hospital, Tehran, Iran
Article information
  • International Journal of Cancer Management: September 2018, 11 (9); e66188
  • Published Online: September 17, 2018
  • Article Type: Research Article
  • Received: January 12, 2018
  • Revised: September 1, 2018
  • Accepted: September 3, 2018
  • DOI: 10.5812/ijcm.66188

To Cite: Mirzaei H, Sabetrasekh P , Sabetrasekh P, Parvin M, Torbati P, et al. Prevalence of the Vascular Endothelial Growth Factor Receptor (VEGER) in Transitional Cell Carcinoma (TCC) of Bladder and its Relationship with Other Prognostic Factors, Int J Cancer Manag. 2018 ; 11(9):e66188. doi: 10.5812/ijcm.66188.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262.
  • 2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi: 10.3322/caac.21166. [PubMed: 23335087].
  • 3. James N, Bryan RT, Viney R, Patel P, Hussain SA. Bladder cancer. In: Perez CA, Brady LW, Halperin EC, Wazer DE, editors. Perez and Brady's principles and practice of radiation oncology. 6th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2013. p. 1259-79.
  • 4. Parvin M, Sabet-Rasekh P, Hajian P, Mohammadi Torbati P, Sabet-Rasekh P, Mirzaei H. Evaluating the prevalence of the epidermal growth factor receptor in transitional cell carcinoma of bladder and its relationship with other prognostic factors. Iran J Cancer Prev. 2016;9(1). e4022. doi: 10.17795/ijcp-4022. [PubMed: 27366313]. [PubMed Central: PMC4922206].
  • 5. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, et al. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer. 2008;8:295. doi: 10.1186/1471-2407-8-295. [PubMed: 18847499]. [PubMed Central: PMC2572070].
  • 6. Gkiozos I, Tsagouli S, Charpidou A, Grapsa D, Kainis E, Gratziou C, et al. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: Results of a prospective study. Anticancer Res. 2015;35(2):1129-37. [PubMed: 25667503].
  • 7. Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol. 2014;9(2):142-60. doi: 10.1007/s11481-014-9531-7. [PubMed: 24610033]. [PubMed Central: PMC4048289].
  • 8. Psatha A, Makris D, Kerenidi T, Daniil Z, Kiropoulos T, Gourgoulianis K. A potential role for VEGF in the diagnostic approach of pleural effusions. J Thorac Dis. 2016;8(7):1681-7. doi: 10.21037/jtd.2016.05.73. [PubMed: 27499957]. [PubMed Central: PMC4958865].
  • 9. Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122-8. doi: 10.2174/157016110790226606. [PubMed: 19485913].
  • 10. Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: Past, present, and future. Ann Oncol. 2016;27 Suppl 1:i33-9. doi: 10.1093/annonc/mdw093. [PubMed: 27141068].
  • 11. Pronto-Laborinho AC, Pinto S, de Carvalho M. Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. Biomed Res Int. 2014;2014:947513. doi: 10.1155/2014/947513. [PubMed: 24987705]. [PubMed Central: PMC4022172].
  • 12. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One. 2010;5(7). e11772. doi: 10.1371/journal.pone.0011772. [PubMed: 20668552]. [PubMed Central: PMC2910721].
  • 13. Barr MP, Gray SG, Gately K, Hams E, Fallon PG, Davies AM, et al. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Mol Cancer. 2015;14:45. doi: 10.1186/s12943-015-0310-8. [PubMed: 25889301]. [PubMed Central: PMC4392793].
  • 14. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50(6):1774-8. [PubMed: 2155059].
  • 15. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262-71. doi: 10.1093/cvr/cvq105. [PubMed: 20400620]. [PubMed Central: PMC2895541].
  • 16. Yang H, Wang Z, Guo Y, Wang Z. Correlation and significance of urinary soluble fas and vascular endothelial growth factor in bladder urothelial cancer. Dis Markers. 2015;2015:383509. doi: 10.1155/2015/383509. [PubMed: 26798188]. [PubMed Central: PMC4698549].
  • 17. Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013;33(6):2381-90. [PubMed: 23749886].
  • 18. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006;175(4):1245-52. doi: 10.1016/S0022-5347(05)00736-6. [PubMed: 16515971].
  • 19. Nabeel Ahmed A. Clinical utility of altered expressions of P53, vascular endothelial growth factor and survivin in patients with bladder cancer. Cancer Res J. 2015;3(2):28. doi: 10.11648/j.crj.20150302.12.
  • 20. Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol. 2017;9(1):33-45. doi: 10.1177/1758834016667179. [PubMed: 28203296]. [PubMed Central: PMC5298449].
  • 21. Rahmani A, Alzohairy M, Khadri H, Mandal AK, Rizvi MA. Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke. Int J Clin Exp Pathol. 2012;5(3):195-202. [PubMed: 22558473]. [PubMed Central: PMC3341674].
  • 22. Khadim MT, Ahmed SA, Khan FA, Ikram A, Shaikh SY. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder. J Pak Med Assoc. 2015;65(8):851-6. [PubMed: 26228330].
  • 23. Sato K, Sasaki R, Ogura Y, Shimoda N, Togashi H, Terada K, et al. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med. 1998;185(3):173-84. [PubMed: 9823778].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments